PROVIGATE, Inc.
Development of a Behavior Modification System Using Minimally/Non-Invasive Weekly Average Blood Glucose Monitoring for Home Use

As of August,2024

City	Year of Establishment	Founder
Bunkyo-ku, Tokyo	2015	Koshin Sekimizu

Partner VC	Latest round of Fundraising	Valuation
-	Series C	Non-Disclosure

Contact Information: 03-5615-8285
info@provigate.com
Website:PROVIGATE, Inc.

Program name

Deep-Tech Startups Support Program

Research theme

Development of a Behavior Modification System Using Minimally/Non-Invasive Weekly Average Blood Glucose Monitoring for Home Use

Business Plan

Conventional self-monitoring methods for blood glucose are highly invasive and costly, which prevents most diabetic patients from performing adequate self-monitoring. To address this issue, this project focuses on glycated albumin (GA) as a weekly average blood glucose marker. Our aim is to demonstrate the feasibility of mass-producing a minimally/non-invasive, cost-effective home blood glucose monitoring system, ultimately realizing a business with projected annual revenue of 500 billion yen and a corporate value of 5 trillion yen.

Research Outline

Non-Disclosure

Phase	Business Area/Field	Research Period	Research Grant Amount
DMP	HealthCare	2024～2026FY	JPY 1,199 million

International collaborative technology demonstration

Countries/Regions	Collaborative activity outline
United States	- Contract with local partners - Relationship development with potential local partner We will investigate whether weekly GA monitoring combined with an app and telemedicine can effectively drive behavioral changes and improve blood glucose levels in the United States, similar to the Kumamoto Phase 2clinical study in Japan, across diverse racial and cultural backgrounds. Additionally, as part of market research, we will assess diabetes-related needs in the U.S., standard treatments, and develop an insurance coverage strategy tailored to FDA requirements as well as Medicare, Medicaid, and private insurance.

Countries/Regions

Collaborative activity outline

United States

- Contract with local partners
- Relationship development with potential local partner

We will investigate whether weekly GA monitoring combined with an app and telemedicine can effectively drive behavioral changes and improve blood glucose levels in the United States, similar to the Kumamoto Phase 2clinical study in Japan, across diverse racial and cultural backgrounds. Additionally, as part of market research, we will assess diabetes-related needs in the U.S., standard treatments, and develop an insurance coverage strategy tailored to FDA requirements as well as Medicare, Medicaid, and private insurance.

Download this page（166KB）

Last Updated : May 22, 2025

PROVIGATE, Inc. Development of a Behavior Modification System Using Minimally/Non-Invasive Weekly Average Blood Glucose Monitoring for Home Use